Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Moderate Buy” from Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has been given an average recommendation of “Moderate Buy” by the sixteen research firms that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $37.47.

Several research analysts have commented on the stock. BMO Capital Markets set a $20.00 price target on shares of Arvinas and gave the stock an “outperform” rating in a report on Wednesday. Stifel Nicolaus lowered their target price on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, February 12th. Oppenheimer downgraded shares of Arvinas from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 11th. Wedbush downgraded shares of Arvinas from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $57.00 to $12.00 in a research report on Wednesday, March 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th.

Insider Activity at Arvinas

In other Arvinas news, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ian Taylor sold 9,020 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 41,572 shares of company stock valued at $695,030. Insiders own 5.23% of the company’s stock.

Institutional Investors Weigh In On Arvinas

Institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in Arvinas during the fourth quarter valued at approximately $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Arvinas by 0.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock valued at $8,311,000 after buying an additional 3,047 shares in the last quarter. Voloridge Investment Management LLC acquired a new position in shares of Arvinas during the fourth quarter worth $749,000. Woodline Partners LP lifted its position in shares of Arvinas by 39.2% during the fourth quarter. Woodline Partners LP now owns 692,733 shares of the company’s stock worth $13,280,000 after purchasing an additional 194,996 shares in the last quarter. Finally, Twinbeech Capital LP acquired a new position in shares of Arvinas during the fourth quarter worth $3,146,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Stock Performance

Arvinas stock opened at $8.43 on Wednesday. The company’s 50 day simple moving average is $17.32 and its 200-day simple moving average is $21.84. The company has a market capitalization of $579.75 million, a price-to-earnings ratio of -3.04 and a beta of 1.95. Arvinas has a 1 year low of $7.91 and a 1 year high of $45.77.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the company earned ($2.53) earnings per share. Equities analysts expect that Arvinas will post -3.81 earnings per share for the current year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.